Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Oct;78(8):1067–1075. doi: 10.1038/bjc.1998.629

A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.

G M Mead 1, M Russell 1, P Clark 1, S J Harland 1, P G Harper 1, R Cowan 1, J T Roberts 1, B M Uscinska 1, G O Griffiths 1, M K Parmar 1
PMCID: PMC2063167  PMID: 9792152

Abstract

Transitional cell carcinomas may arise at any site within the urinary tract and are a source of considerable morbidity and mortality. In particular, patients with metastatic disease have a poor prognosis, with less than 5% alive at 5 years. A multicentre randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced or metastatic transitional cell carcinoma was conducted in the UK. From April 1991 to June 1995, 214 patients were entered by 16 centres, 108 randomized to CMV and 106 to MV. A total of 204 patients have died. The hazard ratio (relative risk of dying) was 0.68 (95% CI 0.51-0.90, P-value = 0.0065) in favour of CMV. This translates to an absolute improvement in 1-year survival of 13%, 16% in MV and 29% in CMV. The median survival for CMV and MV was 7 months and 4.5 months respectively. Two hundred and eight patients objectively progressed or died. The hazard ratio was 0.55 (95% CI 0.41-0.73, P-value = 0.0001) in favour of CMV. Two hundred and nine patients symptomatically progressed or died. The hazard ratio was 0.48 (95% CI 0.36-0.64, P-value = 0.0001) in favour of CMV. The most important pretreatment factors influencing overall survival were WHO performance status and extent of disease. These two factors were used to derive a prognostic index which could be used to categorize patients into three prognostic groups. We conclude that the addition of cisplatin to methotrexate and vinblastine should be considered in patients with transitional cell carcinoma, taking into account the increased toxicity.

Full text

PDF
1074

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed T., Yagoda A., Needles B., Scher H. I., Watson R. C., Geller N. Vinblastine and methotrexate for advanced bladder cancer. J Urol. 1985 Apr;133(4):602–604. doi: 10.1016/s0022-5347(17)49106-3. [DOI] [PubMed] [Google Scholar]
  2. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  3. Fosså S. D., Sternberg C., Scher H. I., Theodore C. H., Mead B., Dearnaley D., Roberts J. T., Skovlund E. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer. 1996 Nov;74(10):1655–1659. doi: 10.1038/bjc.1996.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jeffery G. M., Mead G. M. CMV chemotherapy for advanced transitional cell carcinoma. Br J Cancer. 1992 Sep;66(3):542–546. doi: 10.1038/bjc.1992.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Loehrer P. J., Sr, Einhorn L. H., Elson P. J., Crawford E. D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M. F., Lowe B. A. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992 Jul;10(7):1066–1073. doi: 10.1200/JCO.1992.10.7.1066. [DOI] [PubMed] [Google Scholar]
  6. Logothetis C. J., Dexeus F. H., Finn L., Sella A., Amato R. J., Ayala A. G., Kilbourn R. G. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990 Jun;8(6):1050–1055. doi: 10.1200/JCO.1990.8.6.1050. [DOI] [PubMed] [Google Scholar]
  8. Roth B. J., Dreicer R., Einhorn L. H., Neuberg D., Johnson D. H., Smith J. L., Hudes G. R., Schultz S. M., Loehrer P. J. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994 Nov;12(11):2264–2270. doi: 10.1200/JCO.1994.12.11.2264. [DOI] [PubMed] [Google Scholar]
  9. Saxman S. B., Propert K. J., Einhorn L. H., Crawford E. D., Tannock I., Raghavan D., Loehrer P. J., Sr, Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997 Jul;15(7):2564–2569. doi: 10.1200/JCO.1997.15.7.2564. [DOI] [PubMed] [Google Scholar]
  10. Seligman P. A., Crawford E. D. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst. 1991 Nov 6;83(21):1582–1584. doi: 10.1093/jnci/83.21.1582. [DOI] [PubMed] [Google Scholar]
  11. Soloway M. S., Einstein A., Corder M. P., Bonney W., Prout G. R., Jr, Coombs J. A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer. 1983 Sep 1;52(5):767–772. doi: 10.1002/1097-0142(19830901)52:5<767::aid-cncr2820520502>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  12. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Geller N., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Bander N. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989 Dec 15;64(12):2448–2458. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  13. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Jr, Bander N., Weiselberg L. R. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988 Mar;139(3):461–469. doi: 10.1016/s0022-5347(17)42494-3. [DOI] [PubMed] [Google Scholar]
  14. Tannock I., Gospodarowicz M., Connolly J., Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989 Aug;142(2 Pt 1):289–292. doi: 10.1016/s0022-5347(17)38733-5. [DOI] [PubMed] [Google Scholar]
  15. Troner M., Birch R., Omura G. A., Williams S. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. J Urol. 1987 Apr;137(4):660–662. doi: 10.1016/s0022-5347(17)44167-x. [DOI] [PubMed] [Google Scholar]
  16. Witte R. S., Elson P., Bono B., Knop R., Richardson R. R., Dreicer R., Loehrer P. J., Sr Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997 Feb;15(2):589–593. doi: 10.1200/JCO.1997.15.2.589. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES